|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE OF ANTI DILUTIVE SECURITIES
| |
|
2025 |
|
|
2024 |
|
| |
|
For the Three Months Ended March 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Convertible notes payable |
|
|
611,034 |
|
|
|
411,430 |
|
| Preferred stock |
|
|
301,900 |
|
|
|
161,673 |
|
| Restricted stock units |
|
|
65,580 |
|
|
|
25,307 |
|
| Warrants to purchase shares of common stock |
|
|
15,483 |
|
|
|
124,159 |
|
| Total potentially dilutive shares |
|
|
993,998 |
|
|
|
722,569 |
|
|